Diabetes and Cardiometabolic Health - Episode 13

Episode 13- Current Developments of Pharmacotherapeutic Spending

EP. 1: Episode 1 - The Prevalence of Comorbid Cardiometabolic Disorders in the US
EP. 2: Episode 3 - The Diversity of Patient Populations
EP. 3: Episode 2 - The Challenges of Disease Management: Clinician and Provider Perspectives
EP. 4: Episode 4 - The Link Between Diabetes and Cardiovascular Disease
EP. 5: Episode 5 - Setting the Tone: Current Therapeutic Goals
EP. 6: Episode 6 - Diabetes and the Burden of Disease
EP. 7: Episode 7 - The Complex Equation of Management
EP. 8: Episode 8 - A Diverse Patient Population and Its Challenges
EP. 9: Episode 9 - Current Challenges and Gaps in Patient Care
EP. 10: Episode 10 - Drivers of Cost in Cardiometabolic Management
EP. 11: Episode 11- Future Outlook on Preventive Care
EP. 12: Episode 12- Comparing Current Healthcare Spending to Patient Outcomes
Now Viewing
EP. 13: Episode 13- Current Developments of Pharmacotherapeutic Spending
EP. 14: Episode 14- Recent Trends in the Epidemiology of Cardiometabolic Conditions
EP. 15: Episode 15- Assessing the Factors at Increased Risk for Cardiometabolic Events
EP. 16: Episode 16- Exploring the Benefits and Limitations of Available Agents
EP. 17: Episode 17 - Evolving Guidelines for the Treatment of Cardiometabolic Events
EP. 18: Episode 18 - Impact of Obesity on Cardiometabolic Events
EP. 19: Episode 19 - - Initiatives Aim to Control Cardiometabolic Events
EP. 20: Episode 20 - Pharmacotherapeutic Initiatives
EP. 21: Episode 21 - Expectations for Newly Developing Agents
EP. 22: Episode 22 - Antiplatelet Agents Explored
EP. 23: Episode 23 - The Affordable Care Act and Healthcare Reform
EP. 24: Episode 24 - Accountable Care Organizations
EP. 25: Episode 25 - Closing Remarks

During this segment, David Calabrese, RPh, MHP, explores the current trends of pharmacotherapeutic spending for the treatment of chronic conditions.

Mr Calabrese explains that from a research and developmental stage, there has been a stronger trend toward investing within the specialty market, rather than on traditional products.

Over 30 new products have been approved in the United States over the past year, and this number is expected to continue to grow annually. For this reason, investors seem more interested in supporting today’s higher-cost, complex therapies rather than traditional products for the treatment of chronic conditions.